FDA Clearance Tracker · K180835
SEKURE Acetaminophen L3K Assay
Last checked: Nov 19, 2026Latest source record: Feb 8, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Feb 8, 2019
Substantially Equivalent
Time to decision
315 days
Received Mar 30, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K180835
- Device name
- SEKURE Acetaminophen L3K Assay
- Applicant
- Sekisui Diagnostics P.E.I., Inc.
- Applicant location
- Charlottetown,, CA
- Received
- Mar 30, 2018
- Decided
- Feb 8, 2019
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Colorimetry, Acetaminophen (LDP)
- Device class
- Class II
- Regulation
- 21 CFR 862.3030
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LDP. The earliest in FDA's data is K801014, decided Jun 20, 1980.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K180835
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Sekisui Diagnostics P.E.I., Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Acetaminophen510(k)
K202644 · Decided Feb 18, 2022 · 525 days after receipt
Device type: Colorimetry, Acetaminophen (LDP) · Laboratory Medicine & Pathology
K182702 · Decided Apr 17, 2019 · 202 days after receipt
Device type: Nad Reduction/Nadh Oxidation, Cpk Or Isoenzymes (CGS) · Laboratory Medicine & Pathology
- SEKURE HbA1c Assay510(k)
K173206 · Decided Jul 12, 2018 · 283 days after receipt
Device type: Hemoglobin A1c Test System (PDJ) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.